DE69125485T2 - Verfahren und zwischenprodukte synthetischer antikörperderivate - Google Patents

Verfahren und zwischenprodukte synthetischer antikörperderivate

Info

Publication number
DE69125485T2
DE69125485T2 DE69125485T DE69125485T DE69125485T2 DE 69125485 T2 DE69125485 T2 DE 69125485T2 DE 69125485 T DE69125485 T DE 69125485T DE 69125485 T DE69125485 T DE 69125485T DE 69125485 T2 DE69125485 T2 DE 69125485T2
Authority
DE
Germany
Prior art keywords
antibody derivatives
synthetic antibody
intermediates
intermediate products
chimeric antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69125485T
Other languages
English (en)
Other versions
DE69125485D1 (de
Inventor
George Stevenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3I Research Exploitation Ltd
Original Assignee
3I Research Exploitation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3I Research Exploitation Ltd filed Critical 3I Research Exploitation Ltd
Application granted granted Critical
Publication of DE69125485D1 publication Critical patent/DE69125485D1/de
Publication of DE69125485T2 publication Critical patent/DE69125485T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
DE69125485T 1990-04-23 1991-04-22 Verfahren und zwischenprodukte synthetischer antikörperderivate Expired - Fee Related DE69125485T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909009106A GB9009106D0 (en) 1990-04-23 1990-04-23 Processes and intermediates for synthetic antibody derivatives
PCT/GB1991/000633 WO1991016354A1 (en) 1990-04-23 1991-04-22 Processes and intermediates for synthetic antibody derivatives

Publications (2)

Publication Number Publication Date
DE69125485D1 DE69125485D1 (de) 1997-05-07
DE69125485T2 true DE69125485T2 (de) 1997-07-24

Family

ID=10674863

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69125485T Expired - Fee Related DE69125485T2 (de) 1990-04-23 1991-04-22 Verfahren und zwischenprodukte synthetischer antikörperderivate

Country Status (7)

Country Link
US (1) US6136313A (de)
EP (1) EP0528856B1 (de)
JP (1) JPH05507268A (de)
AT (1) ATE151078T1 (de)
DE (1) DE69125485T2 (de)
GB (1) GB9009106D0 (de)
WO (1) WO1991016354A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0759782A1 (de) * 1994-05-26 1997-03-05 Innogenetics N.V. Verfahren und Verbindungen zur selektiven Modulation des antigenspezifischenT - Zelltreaktorvermögens
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030157091A1 (en) * 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
DK2298347T3 (en) 2003-05-06 2016-01-11 Biogen Hemophilia Inc COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1641827A2 (de) * 2003-06-27 2006-04-05 Biogen Idec MA Inc. Verwendung der hydrophoben-interaktions-chromatographie oder hinge-regionen modifikationen zur herstellung homogener antikörperlösungen
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
WO2005063816A2 (en) * 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
US20070014789A1 (en) * 2005-07-15 2007-01-18 Bayer Healthcare Llc Humanized antibody conjugates and related methods, assays, reagents, and kits
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
US20110129414A1 (en) * 2005-11-15 2011-06-02 Balyasnikova Irina V Single Chain Fragment of Monoclonal Antibody 9B9 and Uses Thereof
US20080108147A1 (en) * 2006-11-03 2008-05-08 Tie Wei Reduction of non-specific binding in immunoassays
NZ581395A (en) * 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2132228B1 (de) 2008-04-11 2011-06-22 Emergent Product Development Seattle, LLC Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
GB8824869D0 (en) * 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
FR2639231A1 (fr) * 1988-11-23 1990-05-25 Merieux Inst Utilisation de fragments fc d'immunoglobulines g humaines, de peptides analogues du fragment fc, ou d'immunoglobulines g humaines dans l'obtention d'un medicament preparatoire a l'administration chez l'homme, dans un but therapeutique ou de diagnostic, d'anticorps monoclonaux

Also Published As

Publication number Publication date
ATE151078T1 (de) 1997-04-15
DE69125485D1 (de) 1997-05-07
US6136313A (en) 2000-10-24
WO1991016354A1 (en) 1991-10-31
EP0528856A1 (de) 1993-03-03
EP0528856B1 (de) 1997-04-02
GB9009106D0 (en) 1990-06-20
JPH05507268A (ja) 1993-10-21

Similar Documents

Publication Publication Date Title
DE69125485D1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
DE69119278D1 (de) Monoklonaler Antikörper, der mit einer neuen HLA-Determinante auf MHC-Klasse-I-Moleküle reagiert, und Verfahren zur Aktivierung von Lymphozyten
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
NO982062D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DE69429095D1 (de) Humanisierte antikoerper
UA48940C2 (uk) Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень
DE69128543D1 (de) Monoklonale antikörper der maus
DE69325393T2 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
DE69029858T2 (de) Behandlung von einer autoimmun-krankheit
DE3686811D1 (de) Verfahren und zusammensetzung zur behandlung von krebs und nichtmalignen tumoren.
SE8404334D0 (sv) 16-fluoro-16,17-didehydro-prostanoids and process for their preparation
FR2571146B1 (fr) Antigenes carcino-foetaux du pancreas humain et un procede de purification, antiserum contre ces antigenes et son procede de preparation et compositions diagnostiques les contenant
ATE222927T1 (de) Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii)
ATE155481T1 (de) Verfahren zur reinigung von streptolysin 0, intaktes streptolysin 0 erhältlich nach diesem verfahren und seine verwendung
HU9300349D0 (en) Method for producing dibenzo- or benzo-pyrido-cyclohepta-piperidine derivatives or piperidylidene or piperazine derivatives thereof as well as pharmaceutical preparatives contqining them
ES2060162T3 (es) Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina.
DK0858465T3 (da) Protein med antitumorvirkning.
DK0421382T3 (da) Monoklonalt antistof mod exotoxin A fra Pseudomonas aeruginosa
OA07542A (fr) Nouveaux dérivés stéroïdes substitués en 11b, procédé et intermédiaires de préparation, leur application comme médicament et les compositions les renfermant.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee